Genese Biotech

Genese Biotech is a South Korean biopharmaceutical company focused on developing first-in-class therapeutics for neurodegenerative and metabolic diseases. The company's core scientific approach is based on protein homeostasis (proteostasis), specifically targeting the cell's internal protein quality control mechanisms. Genese Biotech utilizes a proprietary discovery platform to identify small molecules that can clear pathological protein aggregates by activating the ubiquitin-proteasome system and autophagy. Its lead candidate, GB001, is being developed for Alzheimer's disease with the aim of reducing cognitive decline through the clearance of toxic proteins. Additionally, the company maintains a growing pipeline of programs for NASH, sarcopenia, and obesity, supported by significant venture capital investment from leading Korean financial institutions.